Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 1999

View Archived Issues

Eisai product pipeline update

Milestone achieved in Warner-Lambert/Unigene collaboration for oral calcitonin product

ID Biomedical seeks U.S. marketing clearance for MRSA test

SomatoKine reduces insulin use, improves glycemic control in type I diabetes

Access to acquire Virologix

FDA issues complete response letter for Rebif BLA

Endorex updates cancer and drug delivery programs

Novel hypoglycemic compounds designed at RPR

Novel vitamin D compounds with favorable biological profile from WARF

Pfizer discloses novel macrolide antibiotics

PDE4 inhibitors claimed by Byk Gulden for airways disorders

Vitronectin receptor antagonists with a benzocycloheptene core designed at SB

Second Ligand/Wyeth-Ayerst SERM to enter clinical trials shortly

Janssen confirms lubeluzole no longer under development

SS Pharm. outlicenses drug candidates to speed development, reduce costs

Alertec approved in Canada for treatment of narcolepsy

Biochemical and pharmacological profile of new MAO-A inhibitor: 2614W94

Cubist Pharmaceuticals initiates pivotal clinical trials for daptomycin

Licensing opportunity from BTG: xanthine oxidase inhibitors for treatment of ARDS

Epothilone analogue markedly suppresses growth of or cures MDR tumors in vivo

RCT supports early-stage life science discoveries originating in New England

Vasoflux is superior to other anticoagulants due to its unique mechanism of action

HFA-134a-BDP controls asthma at half the dose of traditional inhalers

Gadophrin-2 in the assessment of infarct size in dogs

Preclinical results obtained with candidate antidiabetic support further testing

Nuvance advances to phase II clinical trials for long-term control of asthma

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...